Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alone should therefore be considered. One promising strategy is to combine low-intensity treatments with novel agents.
CITATION STYLE
Thomas, X. (2015). Acute Myeloid Leukemia in the Elderly Patient: New Strategies. Rare Cancers and Therapy, 3(1–2), 1–11. https://doi.org/10.1007/s40487-015-0006-7
Mendeley helps you to discover research relevant for your work.